Quince Therapeutics, Inc. (IRLA): Capital Expenditures
$352.0K
Year ended 2025-12-31
$78.0K
Trailing 12 months to 2026-06-30
+38.3%
3-year compound annual growth
+46.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $352.0K | +37.0% | 2026-04-10, From 2025-01-01 |
| 2024-12-31 | $257.0K | +60.6% | 2026-04-10, From 2024-01-01 |
| 2023-12-31 | $160.0K | +20.3% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $133.0K | -26.1% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $180.0K | +246.2% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $52.0K | -5.5% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $55.0K | -74.1% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $212.0K | n/a | 2021-03-01, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (IRLA) | 2025-12-31 | $352.0K | +37.0% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $77.0K | +18.5% |
| LeonaBio, Inc. (LONA) | 2024-12-31 | $33.0K | -89.1% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $128.0K | +392.3% |
| Aligos Therapeutics, Inc. (ALGS) | 2024-12-31 | $130.0K | +584.2% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $1.64M | +27.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $293.5K | +999.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $542.0K | -71.2% |
Compare IRLA, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗